Rigel Pharmaceuticals reported $0 in Loan Capital for its fiscal quarter ending in September of 2024.





Loan Capital Change Date
Agenus USD 153.98M 15.68M Mar/2026
Amgen USD 51.61B 250M Sep/2026
Arrowhead Research USD 824.07M 401.34M Jun/2026
AstraZeneca USD 28.8B 2.79B Sep/2026
BioMarin Pharmaceutical USD 3.51B 12.96M Sep/2026
Bristol-Myers Squibb USD 41.85B 244M Sep/2026
Daiichi Sankyo JPY 499.93B 75M Sep/2026
Eli Lilly USD 46.99B 872M Sep/2026
Halozyme Therapeutics USD 2.94B 1.01B Sep/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Intrexon USD 0 198.67M Jun/2024
Ionis Pharmaceuticals USD 1.77B 140.62M Sep/2026
Karyopharm Therapeutics USD 264.49M 13.73M Mar/2026
Ligand Pharmaceuticals USD 1.13B 679.7M Jun/2026
MacroGenics USD 163.16M 94.44M Jun/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Pfizer USD 60B 498M Sep/2026
Regeneron Pharmaceuticals USD 1.99B 400K Sep/2026
Rigel Pharmaceuticals USD 0 0 Sep/2024
Sangamo BioSciences USD 0 0 Jun/2022
Ultragenyx Pharmaceutical USD 1.13B 2M Jun/2026
Veracyte USD 0 0 Mar/2025